Drug news
NICE requests more information on Aubagio
The National Institute for Health and Care Excellence (NICE) requires Sanofi/ Genzyme to provide more information on Aubagio (teriflunomide) for Multiple Sclerosis. In draft guidance published for consultation, NICE has requested a more information on the evidence submitted by Sanofi/Genzyme. This draft guidance has now been issued for consultation: NICE has not yet published final guidance to the NHS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.